SU11274 is primarily utilized in biochemical research as a potent and selective inhibitor of the c-Met receptor tyrosine kinase. This application is significant in studying cellular signaling pathways, particularly those involved in cancer progression and metastasis. By inhibiting c-Met, SU11274 helps researchers understand the role of this receptor in tumor growth, invasion, and angiogenesis. It is often employed in in vitro and in vivo experiments to explore potential therapeutic strategies targeting c-Met-driven cancers, such as certain types of lung, liver, and gastric cancers. Additionally, SU11274 serves as a valuable tool for investigating the mechanisms of drug resistance and identifying synergistic effects with other anticancer agents.